Abstract P1-10-16: Ethnicity, recurrence score (RS) distribution, and clinical outcomes in ER+ HER2-negative breast cancer (BC) patients (pts) in Israel
Gil Bar‐Sela(Emek Medical Center), Salomon M. Stemmer(Tel Aviv University), Georgeta Fried(Roche (Switzerland)), Noa Ben-Baruch(Kaplan Medical Center), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Nicky Liebermann(Clalit Health Services), Margarita Tokar, Bella Kaufman(NYU Langone Health), Avital Bareket‐Samish, Ariel Hammerman(Clalit Health Services), Rinat Yerushalmi(Rabin Medical Center), Michelle Leviov(Haifa Medical Center), Iryna Kuchuk(University of Ottawa), Tamar Peretz(Hadassah Medical Center), Shani Paluch–Shimon(Hebrew University of Jerusalem), Samih Yousef(Emek Medical Center), Amir Sonnenblick(Tel Aviv University)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k